Women experience physiological and emotional issues during different phases of their life cycle due to hormonal changes. Women's health is especially referred to where reproductive health is involved. According to the Society for Women's Health Research in the US, issues specific to the human female anatomy are defined as women's health. The biological mechanisms influence the clinical course of diseases and disorders differently in women when compared to men.
Some of the main women's health disorders include infertility, menopause, endometriosis and polycystic ovarian syndrome as well as urological disorders and cancers such as breast cancer, cervical cancer, endometrial cancer, and ovarian cancer. In addition, contraception plays an important role in women's health for many reasons, so this too is also categorized under women's health.
The analysts forecast the Global Women's Health market will grow at a CAGR of 3.52 percent over the period 2013-2018.
This report covers the present scenario and the growth prospects of the Global Women's Health market for the period 2014-2018. To calculate the market size, the report considers revenue generated from the sales of various products used for the wellbeing of women, which are listed below based on their application segment:
- Postmenopausal Osteoporosis (Drugs)
- Hormonal Contraceptives (Drugs and Devices)
- Menopause (Drugs)
- Infertility (Drugs)
- Endometriosis (Drugs)
- Polycystic Ovary Syndrome (Drugs)
The report, the Global Women's Health Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the EMEA, and the APAC regions; it also covers the Global Women's Health market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
In the recent past, vendors have entered into several agreements or partnerships to develop or introduce new products or drugs in the Global Women's Health market. Some of the major acquisitions include Conceptus by Bayer, Warner Chilcott by Actavis, Uteron Pharma by Watson Pharmaceuticals, and Barr Pharmaceuticals by Teva Pharmaceutical.
Some of the other prominent collaborations include Bayer with EndoCeutics to develop Vaginorm for treatment of vaginal atrophy, AbbVie with Neurocrine Biosciences to develop and commercialize Elagolix and all next-generation GnRH antagonists for women's and men's health.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
06. Market Landscape
07. Market Segmentation by Application
08. Global Postmenopausal Osteoporosis Market
09. Global Hormonal Contraceptives Market
10. Global Menopause Market
11. Global Infertility Market
12. Global Endometriosis Market
13. Global Polycystic Ovary Syndrome Market
14. Geographical Segmentation
15. Buying Criteria
16. Market Growth Drivers
17. Drivers and their Impact
18. Market Challenges
19. Impact of Drivers and Challenges
20. Market Trends
21. Trends and their Impact
22. Vendor Landscape
23. Key Vendor Analysis
24. Other Reports in this Series
- Actavis plc
- Agile Therapeutics
- AstraZeneca plc
- Bayer AG
- Blairex Laboratories
- Catalysis SL
- Dexa Medica Group
- Eli Lilly and Co.
- Ferring International Center SA
- GlaxoSmithKline plc
- HLL Lifecare Ltd.
- Mayer Laboratories
- Medicines 360
- Merck & Co.
- Mylan Laboratories
- Neurocrine Biosciences
- Pantarhei Bioscience BV
For more information visit http://www.researchandmarkets.com/research/k9lp65/global_womens
Media Contact: Laura Wood, +353-1-481-1716, email@example.com
SOURCE Research and Markets